Nyxoah Appoints Loic Moreau As Interim CFO, Effective Oct. 2, Succeeding John Landry; Reiterates FY26 Revenue Range Of €36M - €40M
Nyxoah SA (Euronext Brussels/NASDAQ: NYXH ) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loïc Moreau, the Company’s President International and former CFO, will serve as Interim CFO effective upon Mr. Landry’s departure while the Company conducts a search for a permanent successor. Nyxoah is reaffirming the financial guidance for the full year 2026 that it previously issued: The Company expects worldwide net revenue for the full year 2026 to be in the range of €36 million to €40 million.
Nyxoah SA (Euronext Brussels/NASDAQ: NYXH ) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loïc Moreau, the Company’s President International and former CFO, will serve as Interim CFO effective upon Mr. Landry’s departure while the Company conducts a search for a permanent successor.
Nyxoah is reaffirming the financial guidance for the full year 2026 that it previously issued: The Company expects worldwide net revenue for the full year 2026 to be in the range of €36 million to €40 million.